3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
39
Ovarian Neoplasms
32
Triple Negative Breast Neoplasms
19
Prostatic Neoplasms
17
Fallopian Tube Neoplasms
16
Neoplasm Metastasis
14
Pancreatic Neoplasms
9
Neoplasms
9
Endometrial Neoplasms
9
Carcinoma, Non-Small-Cell Lung
7
Small Cell Lung Carcinoma
6
Parkinson Disease 4, Autosomal Dominant Lewy Body
6
Glioma
6
Stomach Neoplasms
5
Sarcoma
5
Lung Neoplasms
5
Glioblastoma
5
Squamous Cell Carcinoma of Head and Neck
4
Metastatic Castration-resistant Prostate Cancer
4
Carcinoma, Ovarian Epithelial
4
Solid Tumors
3
Recurrence
3
Osteosarcoma
3
Neuroendocrine Tumors
3
Lymphoma, Non-Hodgkin
3
Cholangiocarcinoma
3
Urinary Bladder Neoplasms
2
Sarcoma, Ewing
2
Rhabdomyosarcoma
2
Prostatic Neoplasms, Castration-Resistant
2
Interventions
enzalutamide
4
Docetaxel
3
abiraterone
2
Prednisone
2
Abiraterone Acetate
2
relugolix
1
pembrolizumab
1
olaparib
1
lenvatinib
1
inavolisib
1
belzutifan
1
apalutamide
1
PF06821497
1
Methylprednisolone
1
Lutetium-177
1
Lutetium
1
Gonadotropin-Releasing Hormone
1
Etoposide
1
Dexamethasone
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Metastatic Castration-Resistant Prostate Cancer
×
olaparib
×
1 year
×
Clear all
NCT02861573
2026-02-17
KEYNOTE-365
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
1,200 enrolled